These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 25189357)
1. HPV vaccination: for women of all ages? Castle PE; Schmeler KM Lancet; 2014 Dec; 384(9961):2178-80. PubMed ID: 25189357 [No Abstract] [Full Text] [Related]
2. Clinical round-up. Herbert S; Haddow L Sex Transm Infect; 2015 May; 91(3):226. PubMed ID: 26065038 [No Abstract] [Full Text] [Related]
3. Gynaecological cancer: HPV vaccine: is age just a number? Stone L Nat Rev Urol; 2014 Nov; 11(11):605. PubMed ID: 25245243 [No Abstract] [Full Text] [Related]
4. Success of HPV vaccination is now a matter of coverage. Schiffman M; Wacholder S Lancet Oncol; 2012 Jan; 13(1):10-2. PubMed ID: 22075169 [No Abstract] [Full Text] [Related]
5. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine. Di Mario S; Basevi V; Borsari S; Balduzzi S; Magrini N Lancet Oncol; 2012 Feb; 13(2):e50; author reply e50. PubMed ID: 22300857 [No Abstract] [Full Text] [Related]
6. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666 [TBL] [Abstract][Full Text] [Related]
7. HPV vaccination: too soon for 2 doses? Kahn JA; Bernstein DI JAMA; 2013 May; 309(17):1832-4. PubMed ID: 23632729 [No Abstract] [Full Text] [Related]
8. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261 [TBL] [Abstract][Full Text] [Related]
9. HPV single-dose vaccination: Impact potential, evidence base and further evaluation. Stanley M; Dull P Vaccine; 2018 Aug; 36(32 Pt A):4759-4760. PubMed ID: 29754700 [No Abstract] [Full Text] [Related]
10. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Schwarz TF Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203 [TBL] [Abstract][Full Text] [Related]
11. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G; Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922 [TBL] [Abstract][Full Text] [Related]
13. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311 [TBL] [Abstract][Full Text] [Related]
16. Who should be targeted for vaccination against anal cancer? Harper DM; Vierthaler SL Lancet Oncol; 2011 Sep; 12(9):828-9. PubMed ID: 21865086 [No Abstract] [Full Text] [Related]
17. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832 [TBL] [Abstract][Full Text] [Related]
18. HPV and cervical cancer: screening or vaccination? Bosch FX; Castellsagué X; de Sanjosé S Br J Cancer; 2008 Jan; 98(1):15-21. PubMed ID: 18182975 [TBL] [Abstract][Full Text] [Related]
20. The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial. Bosch FX; de Sanjose S; Castellsague X Cancer Discov; 2011 Oct; 1(5):377-80. PubMed ID: 22586628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]